Merck's Pneumonia Shot Recommended For Healthy Adults Ages 65+ And As Interchangeable With Pfizer's Prevnar
Portfolio Pulse from Benzinga Newsdesk
Merck's pneumonia vaccine has been recommended for healthy adults aged 65 and older and as interchangeable with Pfizer's Prevnar, according to Bloomberg.
June 27, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's Prevnar is now considered interchangeable with Merck's pneumonia vaccine, which may lead to increased competition and potential market share loss.
The interchangeability of Pfizer's Prevnar with Merck's vaccine could result in increased competition, potentially affecting Pfizer's market share and revenues negatively.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Merck's pneumonia vaccine has been recommended for healthy adults aged 65 and older, which could boost its market share and revenues.
The recommendation for Merck's pneumonia vaccine for healthy adults aged 65+ is likely to increase its adoption and sales, positively impacting the company's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100